nc-190 has been researched along with Carcinoma--Small-Cell* in 1 studies
1 review(s) available for nc-190 and Carcinoma--Small-Cell
Article | Year |
---|---|
[DNA topoisomerase inhibitor].
CPT-11 and Topotecan are a new semisynthetic derivative of CPT, and have been shown to inhibit DNA topoisomerase I and to have a strong antitumor activity with low toxicity against murine tumor. On the other hard, the new antitumor compounds, NC-190 and IST-622 have been shown to inhibit DNA topoisomerase II, and the clinical study are currently under progress. A phase II study of CPT-11 demonstrated that CPT-11 was a very active agent which a acceptable toxicities against patient with advanced non-small cell lung cancer and small cell lung cancer. Topics: Animals; Antineoplastic Agents; Camptothecin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Drug Administration Schedule; Female; Humans; Irinotecan; Lung Neoplasms; Male; Mice; Phenazines; Topoisomerase I Inhibitors; Topotecan | 1992 |